These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 21061574)

  • 21. [The inoculative properties of cold-adapted reassortant A(H5N2) influenza strain during intranasal administration to mice].
    Desheva IuA; Lu Kh; Rekstin AR; Kats DM; Rudenko LG; Klimov AI
    Vopr Virusol; 2007; 52(4):27-30. PubMed ID: 17722607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Activating effect of a germanium-organic compound on immunocompetent cells during intranasal immunization of mice with a live influenza vaccine].
    Liashenko VA; Akhmatova NK; Ambrosov IV; Matelo SK; Markushin SG; Akhmatov ÉA; Sukhno AS; Khomenkov VG
    Zh Mikrobiol Epidemiol Immunobiol; 2013; (3):60-8. PubMed ID: 24000595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus.
    Moon HJ; Lee JS; Talactac MR; Chowdhury MY; Kim JH; Park ME; Choi YK; Sung MH; Kim CJ
    Vet Microbiol; 2012 Dec; 160(3-4):277-89. PubMed ID: 22763171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung.
    Proudfoot O; Esparon S; Tang CK; Laurie K; Barr I; Pietersz G
    BMC Infect Dis; 2015 Feb; 15():101. PubMed ID: 25887952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
    Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cold-adapted strain of A/Leningrad/134/47/57 (H2N2)--a special attenuation donor of live influenza vaccine for children and the isolation of its recombinants].
    Garmashova LM; Polezhaev FI; Aleksandrova GI
    Vopr Virusol; 1984; 29(1):28-31. PubMed ID: 6710978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine.
    Hagenaars N; Verheul RJ; Mooren I; de Jong PH; Mastrobattista E; Glansbeek HL; Heldens JG; van den Bosch H; Hennink WE; Jiskoot W
    J Control Release; 2009 Dec; 140(2):126-33. PubMed ID: 19712713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cold-adapted X-31 live attenuated 2009 pandemic H1N1 influenza vaccine elicits protective immune responses in mice and ferrets.
    Jang YH; Byun YH; Lee DH; Lee KH; Lee YJ; Lee YH; Park JK; Song CS; Seong BL
    Vaccine; 2013 Feb; 31(9):1320-7. PubMed ID: 23313655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Influence of chitosan on immunophenotype and functional activity of murine mononuclear leukocytes after immunization with inactivated influenza vaccine].
    Akhmatova NK; Egorova NB; Kurbatova EA; Semenova IB; Kuz'menko OM; Shcherbakov RV; Markushin SG; Gendon IuZ
    Zh Mikrobiol Epidemiol Immunobiol; 2008; (6):31-5. PubMed ID: 19186542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and protective efficacy of cold-adapted X-31 live attenuated pre-pandemic H5N1 influenza vaccines.
    Jang YH; Jung EJ; Byun YH; Lee KH; Lee EY; Lee YJ; Seong BL
    Vaccine; 2013 Jul; 31(33):3339-46. PubMed ID: 23742997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Increasing the immunogenicity of inactivated chitosan adjuvanted vaccine from A/California/7/09 (H1N1) strain and analyzing the antigenic specificity of this influenza virus strain].
    Gendon IuZ; Markushin SG; Vasil'ev IuM; Akopova II; Krivtsov GG
    Vopr Virusol; 2012; 57(1):28-33. PubMed ID: 22624470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets.
    Maltais AK; Stittelaar KJ; Veldhuis Kroeze EJ; van Amerongen G; Dijkshoorn ML; Krestin GP; Hinkula J; Arwidsson H; Lindberg A; Osterhaus AD
    Vaccine; 2014 May; 32(26):3307-15. PubMed ID: 24690149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Role of individual genes in expression of phenotypic properties of the cold-adapted strain A/Leningrad/134/47/57 (H2N2)-a donor of attenuation of live influenza vaccine].
    Medvedeva TE; Kudriavtseva VK; Nevedomskaia GN; Zhikhareva IV; Gushchina MI; Zolotarev FN; Vodeĭko GM; Lisovskaia KV; Iotov VV; Khaĭder MI
    Genetika; 1993 Apr; 29(4):681-9. PubMed ID: 8354475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Safety and high immunogenicity for children 3 to 15 of a mono- and a divaccine from recombinant influenza A/Brazil /11/78 (H1N1) and A/Bangkok/1/79 (H3N2) viruses obtained from a special donor attenuation base--the cold-adapted virus A/Leningrad/134/47/57 (H2N2)].
    Polezhaev FI; Budilovskiĭ GN; Garmashova LM; Romeĭko-Gurko IuR; Egorov AIu
    Vopr Virusol; 1983; 28(6):710-4. PubMed ID: 6670253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of a novel cold-adapted modified-live equine influenza virus vaccine.
    Tabynov K; Kydyrbayev Z; Ryskeldinova S; Assanzhanova N; Kozhamkulov Y; Inkarbekov D; Sansyzbay A
    Aust Vet J; 2014 Nov; 92(11):450-7. PubMed ID: 25348146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A bivalent live-attenuated influenza vaccine for the control and prevention of H3N8 and H3N2 canine influenza viruses.
    Rodriguez L; Nogales A; Murcia PR; Parrish CR; Martínez-Sobrido L
    Vaccine; 2017 Aug; 35(34):4374-4381. PubMed ID: 28709557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.
    Boonnak K; Matsuoka Y; Wang W; Suguitan AL; Chen Z; Paskel M; Baz M; Moore I; Jin H; Subbarao K
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28490598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian influenza virus challenge.
    Wang SH; Smith D; Cao Z; Chen J; Acosta H; Chichester JA; Yusibov V; Streatfield SJ; Fattom A; Baker JR
    Vaccine; 2019 Mar; 37(12):1591-1600. PubMed ID: 30795941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [COMPARATIVE IMMUNOGENICITY STUDIES OF ADJUVANTS FROM VARIOUS SOURCES AND WITH DIFFERENT MECHANISMS OF ACTION FOR INACTIVATED INFLUENZA VACCINES].
    Chernikova MI; Kashirina OS; Vasiliev YM
    Zh Mikrobiol Epidemiol Immunobiol; 2015; (6):63-71. PubMed ID: 26950991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.